Recursion Pharmaceuticals, Inc. 8-K Filing
Ticker: RXRX · Form: 8-K · Filed: Dec 8, 2025 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K |
| Filed Date | Dec 8, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Recursion Pharmaceuticals, Inc. (ticker: RXRX) to the SEC on Dec 8, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.00001 (stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar).
How long is this filing?
Recursion Pharmaceuticals, Inc.'s 8-K filing is 2 pages with approximately 488 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 488 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-12-08 07:31:44
Key Financial Figures
- $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
Filing Documents
- rxrx-20251208.htm (8-K) — 22KB
- exhibit991-fappr.htm (EX-99.1) — 37KB
- fapdecember2025webinarde.htm (EX-99.2) — 60KB
- fapdecember2025webinarde001.jpg (GRAPHIC) — 114KB
- fapdecember2025webinarde002.jpg (GRAPHIC) — 232KB
- fapdecember2025webinarde003.jpg (GRAPHIC) — 146KB
- fapdecember2025webinarde004.jpg (GRAPHIC) — 81KB
- fapdecember2025webinarde005.jpg (GRAPHIC) — 108KB
- fapdecember2025webinarde006.jpg (GRAPHIC) — 93KB
- fapdecember2025webinarde007.jpg (GRAPHIC) — 99KB
- fapdecember2025webinarde008.jpg (GRAPHIC) — 140KB
- fapdecember2025webinarde009.jpg (GRAPHIC) — 139KB
- fapdecember2025webinarde010.jpg (GRAPHIC) — 148KB
- fapdecember2025webinarde011.jpg (GRAPHIC) — 44KB
- fapdecember2025webinarde012.jpg (GRAPHIC) — 152KB
- fapdecember2025webinarde013.jpg (GRAPHIC) — 119KB
- fapdecember2025webinarde014.jpg (GRAPHIC) — 164KB
- fapdecember2025webinarde015.jpg (GRAPHIC) — 157KB
- fapdecember2025webinarde016.jpg (GRAPHIC) — 140KB
- fapdecember2025webinarde017.jpg (GRAPHIC) — 107KB
- fapdecember2025webinarde018.jpg (GRAPHIC) — 59KB
- fapdecember2025webinarde019.jpg (GRAPHIC) — 122KB
- fapdecember2025webinarde020.jpg (GRAPHIC) — 97KB
- fapdecember2025webinarde021.jpg (GRAPHIC) — 133KB
- fapdecember2025webinarde022.jpg (GRAPHIC) — 140KB
- fapdecember2025webinarde023.jpg (GRAPHIC) — 114KB
- fapdecember2025webinarde024.jpg (GRAPHIC) — 111KB
- fapdecember2025webinarde025.jpg (GRAPHIC) — 153KB
- fapdecember2025webinarde026.jpg (GRAPHIC) — 147KB
- fapdecember2025webinarde027.jpg (GRAPHIC) — 39KB
- fapdecember2025webinarde028.jpg (GRAPHIC) — 100KB
- fapdecember2025webinarde029.jpg (GRAPHIC) — 133KB
- fapdecember2025webinarde030.jpg (GRAPHIC) — 106KB
- fapdecember2025webinarde031.jpg (GRAPHIC) — 55KB
- fapdecember2025webinarde032.jpg (GRAPHIC) — 68KB
- fapdecember2025webinarde033.jpg (GRAPHIC) — 149KB
- fapdecember2025webinarde034.jpg (GRAPHIC) — 23KB
- fapdecember2025webinarde035.jpg (GRAPHIC) — 124KB
- fapdecember2025webinarde036.jpg (GRAPHIC) — 70KB
- fapdecember2025webinarde037.jpg (GRAPHIC) — 60KB
- fapdecember2025webinarde038.jpg (GRAPHIC) — 168KB
- fapdecember2025webinarde039.jpg (GRAPHIC) — 113KB
- fapdecember2025webinarde040.jpg (GRAPHIC) — 119KB
- fapdecember2025webinarde041.jpg (GRAPHIC) — 118KB
- fapdecember2025webinarde042.jpg (GRAPHIC) — 118KB
- image_0.jpg (GRAPHIC) — 376KB
- image_1.jpg (GRAPHIC) — 315KB
- image_2.jpg (GRAPHIC) — 476KB
- 0001601830-25-000174.txt ( ) — 8518KB
- rxrx-20251208.xsd (EX-101.SCH) — 2KB
- rxrx-20251208_lab.xml (EX-101.LAB) — 21KB
- rxrx-20251208_pre.xml (EX-101.PRE) — 12KB
- rxrx-20251208_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On December 8, 2025, Recursion Pharmaceuticals, Inc. ("Recursion" or the "Company") issued a press release announcing Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. Also on December 8, 2025, the Company released a presentation of the data from the TUPELO Trial. A copy of the presentation is attached hereto as Exhibit 99.2 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of Recursion Pharmaceuticals, Inc. dated December 8, 2025. 99.2 Presentation of Recursion Pharmaceuticals, Inc. dated December 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on December 8, 2025. RECURSION PHARMACEUTICALS, INC. By: /s/ Nathan Hatfield Nathan Hatfield Chief Legal Officer